- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06247553
To Develop a Walking Exercise Program for Non-ambulatory Stroke Survivors
The goal of this clinical trial is to test a gait (walking) training program in non-ambulatory (unable to walk) chronic stroke survivors. The main question it aims to answer is:
• Will gait training improve the cardiovascular system in non-ambulatory chronic stroke survivors better than a sitting leg cycling exercise?
Participants will walk on a treadmill with a partial body-weight support system and the gait training device. Researchers will compare with a leg-cycling exercise to see if there are significant differences in resting heart rate, systolic blood pressure (SBP), and A1c levels in the blood.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Carrie Bailey, MA
- Phone Number: 402-709-8841
- Email: cbailey8@kumc.edu
Study Contact Backup
- Name: Wen Liu
- Phone Number: 913-588-4565
- Email: wliu@kumc.edu
Study Locations
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- Recruiting
- University of Kansas Medical Center
-
Contact:
- Wen Liu
- Phone Number: 913-588-4565
- Email: wliu@kumc.edu
-
Contact:
- Carrie Bailey
- Email: cbailey8@kumc.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- must be 18 to 80 years old
- male or female
- independent ambulation before stroke
- able to understand and follow verbal commands in English
- have physicians' approval for exercise
- be in a stable medical condition
- must be after the first stroke
- unable to walk independently
- in the chronic stage (at least 6 months after stroke onset)
Exclusion Criteria:
- musculoskeletal or other disorders that prevent the participant from participating in the exercise
- blood pressure higher than 200/110 mm Hg
- diagnosis of severe depression
- functionally restricted passive movement in the major joints of lower limbs
- unable to speak or understand English
- unable to travel to the Research Laboratory
- currently participate in other walking training using treadmill with or without a body-weight support system
- body weight greater than 400 lbs
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Gait Training
The gait training in the experimental group will use a treadmill with a partial body-weight support system and our gait training device.
A gait training session will include 2-minute warming up at the beginning and 2-minute cooling down at the end, at a treadmill speed of 0.6 mph.
After the warming up, the treadmill speed will increase at every two minutes by an increment of 0.2 mph.
Participant's heart rate will be monitored throughout the training session by using a Polar OH1 optical HR sensor placed in the participant's left forearm.
Reseachers will stop the increase and maintain the same treadmill speed after the HR reaching the target heart rate zone of 50% - 60% of age-predicted heart rate reserve.
|
The gait training in the experimental group will use a treadmill with a partial body-weight support system and our gait training device.
A gait training session will include 2-minute warming up at the beginning and 2-minute cooling down at the end, at a treadmill speed of 0.6 mph.
After the warming up, the treadmill speed will increase at every two minutes by an increment of 0.2 mph.
Participant's heart rate will be monitored throughout the training session by using a Polar OH1 optical HR sensor placed in the participant's left forearm.
Researchers will stop the increase and maintain the same treadmill speed after the HR reaching the target heart rate zone of 50% - 60% of age-predicted heart rate reserve.
|
Active Comparator: Leg Cycling Exercise
The leg cycling exercise will use a stationary bicycle and the similar protocol as in the experimental group.
The cycling exercise will include 2-minute warming up in the beginning and 2-minute cooling down at the end with a speed of 10 rpm and resistance of level 1 of 4. After warming up, the speed will increase at every two minutes by an increment of 5 rpm until reaching the target heart rate zone of 50% - 60% of age-predicted maximum heart rate.
If the participant cannot tolerate any more increase in cycling speed before reaching the target heart rate, the resistance will be increased.
The training duration will be individualized at the beginning and increase weekly by 5 minutes, depending on the tolerance of the participant, up to the maximum of 30 minutes.
Both heart rate and blood pressure will be monitored before, during, and after each session to ensure safety.
Each session including setting up will be about one hour.
|
The leg cycling exercise will use a stationary bicycle and the similar protocol as in the experimental group.
The cycling exercise will include 2-minute warming up in the beginning and 2-minute cooling down at the end with a speed of 10 rpm and resistance of level 1 of 4. After warming up, the speed will increase at every two minutes by an increment of 5 rpm until reaching the target heart rate zone of 50% - 60% of age-predicted maximum heart rate.
If the participant cannot tolerate any more increase in cycling speed before reaching the target heart rate, the resistance will be increased.
The training duration will be individualized at the beginning and increase weekly by 5 minutes, depending on the tolerance of the participant, up to the maximum of 30 minutes.
Both heart rate and blood pressure will be monitored before, during, and after each session to ensure safety.
Each session including setting up will be about one hour.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
changes in resting heart rate (rHR)
Time Frame: All participants will be assessed at baseline (during the evaluation) and at the end of the 8-week intervention.
|
Resting heart rate (measured in beats per minute) will be measured using a Polar heart rate monitoring system.
|
All participants will be assessed at baseline (during the evaluation) and at the end of the 8-week intervention.
|
systolic blood pressure (SBP)
Time Frame: All participants will be assessed at baseline (during the evaluation) and at the end of the 8-week intervention.
|
Systolic blood pressure (measured in mmHg) will be measured using a mercury sphygmomanometer.
|
All participants will be assessed at baseline (during the evaluation) and at the end of the 8-week intervention.
|
glycated hemoglobin (HbA1c)
Time Frame: All participants will be assessed at baseline (during the evaluation) and at the end of the 8-week intervention.
|
HbA1c levels will be measured by collecting a drop of blood from the middle finger of the unaffected hand and use the A1CNow+ System for analysis.
|
All participants will be assessed at baseline (during the evaluation) and at the end of the 8-week intervention.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
changes in diastolic blood pressure (DBP)
Time Frame: All participants will be assessed at baseline (during the evaluation) and at the end of the 8-week intervention.
|
Diastolic blood pressure (measured in mmHg) will be measured using a mercury sphygmomanometer.
|
All participants will be assessed at baseline (during the evaluation) and at the end of the 8-week intervention.
|
changes in forced vital capacity (FVC)
Time Frame: All participants will be assessed at baseline (during the evaluation) and at the end of the 8-week intervention.
|
To obtain FVC measurements (measured in liters (L)) nose clip will be used, and subject's lips will be sealed around the mouthpiece to prevent air from leaking.
The study team member will verbally encourage the subject to keep inhaling and exhaling at the maximum capacity.
For FVC measurement, the subject will be instructed to maximally inhale, and immediately exhale forcibly and maximally.
This test will be repeated at least three times.
At least one minute will be allowed between each repetition to avoid fatigue.
|
All participants will be assessed at baseline (during the evaluation) and at the end of the 8-week intervention.
|
clinical measurement of Functional Ambulation Category (FAC)
Time Frame: All participants will be assessed at baseline (during the evaluation) and at the end of the 8-week intervention.
|
The measurement of FAC will determine an individual's walking ability based on the amount of human assistance needed.
It includes six categories, with Category 0 indicating nonfunctional ambulation and Category 5 - independent ambulation on varying surfaces.
|
All participants will be assessed at baseline (during the evaluation) and at the end of the 8-week intervention.
|
changes in exercise heart rate (eHR)
Time Frame: These will be measured pre- and post-exercise for the intervention group.
|
Heart rate will be obtained using a Polar heart rate monitoring system.
|
These will be measured pre- and post-exercise for the intervention group.
|
changes in low-density lipoprotein cholesterol (LDL-C)
Time Frame: All participants will be assessed at baseline (during the evaluation) and at the end of the 8-week intervention.
|
A blood sample will be drawn from the antecubital vein in the unaffected arm to be analyzed for plasma cholesterol (LDL-C) levels.
|
All participants will be assessed at baseline (during the evaluation) and at the end of the 8-week intervention.
|
changes in vital capacity (VC)
Time Frame: All participants will be assessed at baseline (during the evaluation) and at the end of the 8-week intervention.
|
To obtain VC measurements (measured in liters (L)) nose clip will be used, and subject's lips will be sealed around the mouthpiece to prevent air from leaking.
The study team member will verbally encourage the subject to keep inhaling and exhaling at the maximum capacity.
The subject will sit and first be asked to breathe normally three times.
The subject will then be instructed immediately to maximally inhale or exhale and repeat four times.
This test will be repeated at least three times.
At least one minute will be allowed between each repetition to avoid fatigue.
|
All participants will be assessed at baseline (during the evaluation) and at the end of the 8-week intervention.
|
changes in Berg Balance Scale (BBS) score
Time Frame: All participants will be assessed at baseline (during the evaluation) and at the end of the 8-week intervention.
|
The BBS is a test consisting of 14 items, designed to measure balance performance in sitting, standing, and weight transfer activities.
The minimum score is 0 and the maximum score is 56.
Higher scores indicate greater balance performance.
|
All participants will be assessed at baseline (during the evaluation) and at the end of the 8-week intervention.
|
changes in muscle activity of the affected leg for participants in the intervention group
Time Frame: All participants will be assessed at baseline (during the evaluation) and at the end of the 8-week intervention.
|
The muscle activity will be measured by the recorded muscle electromyogram (EMG) signals.
|
All participants will be assessed at baseline (during the evaluation) and at the end of the 8-week intervention.
|
changes in heart rate variability (HRV)
Time Frame: All participants will be assessed at baseline (during the evaluation) and at the end of the 8-week intervention.
|
Heart rate variability will be obtained using electrocardiography (ECG).
|
All participants will be assessed at baseline (during the evaluation) and at the end of the 8-week intervention.
|
changes in stroke volume (SV)
Time Frame: All participants will be assessed at baseline (during the evaluation) and at the end of the 8-week intervention.
|
Stroke Volume (SV), an indication of cardiac functioning, will be measured by non-invasive impedance cardiography.
|
All participants will be assessed at baseline (during the evaluation) and at the end of the 8-week intervention.
|
changes in cardiac output (CO)
Time Frame: All participants will be assessed at baseline (during the evaluation) and at the end of the 8-week intervention.
|
Cardiac Output (CO), an indication of cardiac functioning, will be measured by non-invasive impedance cardiography.
|
All participants will be assessed at baseline (during the evaluation) and at the end of the 8-week intervention.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
changes in PASS, Postural Assessment Scale for Stroke Patients
Time Frame: All participants will be assessed at baseline (during the evaluation) and at the end of the 8-week intervention.]
|
The PASS has 12 items that assess balancing ability.
The minimum score is 0 and the maximum score is 36.
Higher scores indicate greater balancing ability.
|
All participants will be assessed at baseline (during the evaluation) and at the end of the 8-week intervention.]
|
changes in TIS, Trunk Impairment Scale
Time Frame: All participants will be assessed at baseline (during the evaluation) and at the end of the 8-week intervention.]
|
The TIS has 17 items that assess trunk functionality and impairment.
The minimum score is 0 and the maximum score is 23.
Higher scores indicate greater trunk functionality and less impairment.
|
All participants will be assessed at baseline (during the evaluation) and at the end of the 8-week intervention.]
|
changes in MI, Motricity Index
Time Frame: All participants will be assessed at baseline (during the evaluation) and at the end of the 8-week intervention.]
|
The MI has 6 items (repeated for each arm and leg) that assess motor impairment in stroke patients.
|
All participants will be assessed at baseline (during the evaluation) and at the end of the 8-week intervention.]
|
changes in RNLI, Reintegration to Normal Living Index
Time Frame: All participants will be assessed at baseline (during the evaluation) and at the end of the 8-week intervention.]
|
The RNLI has 11 items to assess the extent of the patient's ability to return to normal living activities.
|
All participants will be assessed at baseline (during the evaluation) and at the end of the 8-week intervention.]
|
changes in MBI, Modified Barthel Index
Time Frame: All participants will be assessed at baseline (during the evaluation) and at the end of the 8-week intervention.]
|
The MBI has 11 items assessing patients' ability complete a variety of self-care tasks.
|
All participants will be assessed at baseline (during the evaluation) and at the end of the 8-week intervention.]
|
changes in HADS, Hospital Anxiety and Depression Scale
Time Frame: All participants will be assessed at baseline (during the evaluation) and at the end of the 8-week intervention.]
|
The HADS has 14 items (7 depression items and 7 anxiety items) to assess depression and anxiety symptoms experienced in the past week.
The minimum score is 0 and the maximum score is 21 for depression and anxiety individuals.
Higher scores on depression items indicate higher depression.
Higher scores on anxiety items indicate higher anxiety.
|
All participants will be assessed at baseline (during the evaluation) and at the end of the 8-week intervention.]
|
MoCA, Montreal Cognitive Assessment
Time Frame: All participants will be assessed at baseline (during the evaluation).
|
The MoCA has 8 items that assess cognitive functioning.
|
All participants will be assessed at baseline (during the evaluation).
|
BMI, Body Mass Index
Time Frame: All participants will be assessed at baseline (during the evaluation) and at the end of the 8-week intervention.]
|
BMI will be measured by obtaining height and weight.
|
All participants will be assessed at baseline (during the evaluation) and at the end of the 8-week intervention.]
|
Collaborators and Investigators
Investigators
- Principal Investigator: Wen Liu, PhD, University of Kansas Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MOD00042952
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stroke
-
University Hospital, GhentRecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Stroke HemorrhagicBelgium
-
Moleac Pte Ltd.RecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, CryptogenicSingapore, Philippines
-
IRCCS San Camillo, Venezia, ItalyRecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke HemorrhagicItaly
-
Moleac Pte Ltd.Not yet recruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, Cryptogenic
-
Vanderbilt University Medical CenterPatient-Centered Outcomes Research Institute; University of Alabama at BirminghamEnrolling by invitationStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Engagement, Patient | Stroke HemorrhagicUnited States
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Michael Smith Foundation for...RecruitingStroke | Stroke, Ischemic | Stroke Hemorrhagic | Chronic StrokeCanada
-
University of CincinnatiMedical University of South Carolina; University of California, Los Angeles; University...RecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke HemorrhagicUnited States
-
University of MinnesotaAmerican Occupational Therapy FoundationRecruitingStroke | Stroke Sequelae | Stroke Hemorrhagic | Stroke IschemicUnited States
-
University of LiegeCompletedStroke, Acute | Stroke Hemorrhagic | Stroke, ComplicationBelgium
-
University Hospital Inselspital, BerneUnknownEmergencies | Stroke, Acute | Stroke Hemorrhagic | Diagnostic Self Evaluation | Strokes Thrombotic | Stroke SyndromeSwitzerland
Clinical Trials on Gait Training
-
Cairo UniversityCompleted
-
VA Office of Research and DevelopmentCompletedTranstibial AmputationUnited States
-
Translational Research Center for Medical Innovation...Moji Medical Center, Kyusyu Rosai HospitalCompleted
-
National Taiwan University HospitalRecruitingParkinson Disease | Gait Disorders, NeurologicTaiwan
-
Hangang Sacred Heart HospitalMinistry of Health, Republic of KoreaCompletedBurns | Gait Disorder, SensorimotorKorea, Republic of
-
National Rehabilitation Center, Seoul, KoreaCompletedStrokeKorea, Republic of
-
Mahidol UniversityUnknownMild Cognitive Impairment
-
University of Sao PauloFederal University of São Paulo; Universidade do Oeste PaulistaRecruiting
-
Shifa Tameer-e-Millat UniversityRecruitingStroke, IschemicPakistan
-
Centre for Interdisciplinary Research in Rehabilitation...CompletedHemiparesis;Poststroke/CVA